The Immune Response Corporation Presents Updated Interim NeuroVax(TM) Data at European MS Meeting

The Immune Response Corporation (Nasdaq:IMNR), abiopharmaceutical company dedicated to becoming a leading immune-basedtherapy company in HIV and multiple sclerosis (MS), announced Friday,Sept. 30, 2005, that NeuroVax(TM) restored normal levels of FOXP3 andregulatory T-cells (T-reg cells) as well as increased IL-10 secretionin MS patients in an ongoing Phase I/II clinical study. FOXP3, T-regcells and IL-10 are known to play important roles in regulating theimmune system and it is believed that affecting these cells may be oneof the mechanisms of action of NeuroVax(TM), the Company'sinvestigational T-cell receptor (TCR) peptide vaccine for thetreatment of MS. The data was presented at the 21st Congress of theEuropean Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS) in Greece.

"The NeuroVax(TM) clinical program continues to show promisingresults and we believe this new data on IL-10 secretion providesanother important step towards understanding the clinical utility ofthe product," said John N. Bonfiglio, Ph.D., president and chiefexecutive officer of The Immune Response Corporation. "Although only asmall number of patients are included in the MRI analysis, the MRIdata suggest that NeuroVax(TM) may decrease the hallmark brain lesionsindicative of MS. This decrease in lesions leads us to believe thatNeuroVax(TM) may have a clinical benefit for MS patients."

The NeuroVax(TM) clinical research presented at ECTRIMS wasconducted by the Company in association with Oregon Health & ScienceUniversity (OHSU). NeuroVax(TM) demonstrated strong immune responses,as measured by limiting dilution assay (LDA), in a sub-group of six MSpatients analyzed after 48 weeks of monthly injections. As a group,they had increased their FOXP3 regulatory T-cells to levels equal tothose seen in healthy controls. Data were also presented from aprevious blinded, controlled trial showing that 12 patients withpositive MRI lesions at baseline all responded immunologically toNeuroVax(TM). Additional MRI analyses showed a decrease in thepercentage of patients with MRI scans showing positive lesions (40% atbaseline vs. 25% at 24 weeks) as well as a two-fold reduction in themean number of Gadolinium positive lesions. In contrast, 12 controlpatients with MRI scans showing positive lesions at baseline showedaverage increases of about two-fold in both parameters during the same24-week period.

Also presented in the poster were preliminary results showing thatNeuroVax(TM) strongly boosted IL-10 secretion in two MS patients. TwoNeuroVax(TM) treated MS patients and two healthy controls were testedfor production of six different cytokines via cultured PBMCsupernatants. Results showed high levels of IL-10 production in bothMS patients indicating that NeuroVax(TM) induced IL-10 production,while the IL-10 secretion in the healthy controls remained atbackground levels.

Autoimmune diseases such as MS may result from the failure oftolerance mechanisms to prevent expansion of pathogenic inflammatoryT-cells. Previous research indicated that MS patients haveabnormalities in FOXP3 message and protein expression levels inperipheral T-reg cells. This observation linked a defect in functionalperipheral immunoregulation to an established genetic marker, FOXP3,previously shown to be associated with maintaining immune toleranceand preventing development of autoimmune diseases. Diminished FOXP3levels indicate impaired immunoregulation by T-reg cells that maycontribute to MS. The Company believes that induction of these T-regcells is important to the mechanism of action for NeuroVax(TM). Thenew data presented at the conference tends to indicate that treatmentwith NeuroVax(TM) does stimulate FOXP3 T-reg cells.

About Multiple Sclerosis and NeuroVax(TM)

Multiple sclerosis (MS) is an autoimmune disease in which theimmune system, the body's principal defense against foreign substancessuch as bacteria, mistakenly attacks normal tissues of the centralnervous system. It afflicts approximately 400,000 people in the UnitedStates and more than 2.5 million worldwide. Specifically, the diseaseresults in damage to a fatty tissue called myelin that surrounds andprotects nerve fibers, creating scarring (sclerosis) that interfereswith the normal transmission of nerve impulses. This damage, in turn,leads to a variety of chronic and highly individual and unpredictableneurological symptoms, ranging from movement and balance problems tovision impairment. The disease is largely caused by activation of aspecific subset of the patient's own white blood cells, pathogenicT-cells, which then attack the myelin and are largely responsible fordisease progression.

The Company postulates that an immune-based therapy containing TCRpeptides with Incomplete Freund's Adjuvant (IFA) stimulates regulatoryT-cells capable of suppressing these autoreactive pathogenic T-cells.NeuroVax(TM), which combines three TCR peptides with IFA, was designedto increase the likelihood of this immune correction. The Company isseeking a corporate partner to advance this program in development andcommercialization.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq:IMNR) is abiopharmaceutical company dedicated to becoming a leading immune-basedtherapy company in HIV and MS. The Company's HIV products are based onits patented whole inactivated virus technology, co-invented byCompany founder Dr. Jonas Salk to stimulate HIV immune responses.REMUNE(R), currently in Phase II clinical trials, is being developedas a first-line treatment for people with early-stage HIV. We haveinitiated development of a new immune-based therapy, IR103, whichincorporates a second-generation immunostimulatory oligonucleotideadjuvant and is currently in Phase I/II clinical trials in Canada,Italy and the United Kingdom.

The Immune Response Corporation is also developing an immune-basedtherapy for MS, NeuroVax(TM), which is currently in Phase II clinicaltrials and has shown potential therapeutic value for thisdifficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

This news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words suchas should, could, will, might, plan, projection, forecast, expect,guidance, potential and developing. Actual results could varymaterially from those expected due to a variety of risk factors,including whether the Company will continue as a going concern andsuccessfully raise proceeds from financing activities sufficient tofund operations and additional clinical trials of REMUNE(R),NeuroVax(TM) or IR103, the uncertainty of successful completion of anysuch clinical trials, the fact that the Company has not succeeded incommercializing any drug, the risk that REMUNE(R), NeuroVax(TM) orIR103 might not prove to be effective as either a therapeutic orpreventive vaccine, whether future trials will be conducted andwhether the results of such trials will coincide with the results ofREMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlierclinical trials. These risks, among others, are set forth in TheImmune Response Corporation's SEC filings including, but not limitedto, its Annual Report on Form 10-K for the year ended December 31,2004 and its subsequent Quarterly Reports filed on Form 10-Q. TheCompany undertakes no obligation to update the results of theseforward-looking statements to reflect events or circumstances aftertoday or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune ResponseCorporation. NeuroVax(TM) is a trademark of The Immune ResponseCorporation.